Cagrilintide Dosage Guide

Complete guide to Cagrilintide dosing protocols, administration methods, and safety considerations for research purposes.

Research Use Only: The dosage information provided is for educational and research purposes. Peptides are not approved by the FDA for human use. Always consult with a healthcare professional.

Recommended Dosage

Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.

Administration Method

Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.

Side Effects to Monitor

Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.

Safety Considerations & Risks

Investigational compound - full safety profile being established. Expected to carry similar warnings to approved amylin analog pramlintide.